Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 13Active not recruiting 6Not yet recruiting 3Enrolling by invitation 1Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 80Neoplasms 61Colorectal Neoplasms 42Prostatic Neoplasms 41Carcinoma, Non-Small-Cell Lung 35Lung Neoplasms 31Multiple Myeloma 23Leukemia, Myeloid, Acute 23Head and Neck Neoplasms 22Pancreatic Neoplasms 15Melanoma 15Squamous Cell Carcinoma of Head and Neck 14Precursor Cell Lymphoblastic Leukemia-Lymphoma 14Ovarian Neoplasms 14Neoplasm Metastasis 14Carcinoma, Hepatocellular 14Recurrence 13Lymphoma, Non-Hodgkin 13Stomach Neoplasms 12Colonic Neoplasms 11Uterine Cervical Neoplasms 10Rectal Neoplasms 10Lymphoma 10Esophageal Neoplasms 10Carcinoma, Renal Cell 10Brain Neoplasms 10Motor Activity 9Kidney Neoplasms 9Myelodysplastic Syndromes 8Lymphoma, Large B-Cell, Diffuse 8

Interventions

trastuzumab biosimilar HLX02 1Trastuzumab 1Taxes 1Radiotherapy 1Radiation 1Paclitaxel 1PF-05280014 1Ontruzant 1Ogivri 1Carboplatin 1CT-P6 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Adenocarcinoma Of Esophagus × 30 days × Clear all
NCT01196390 2026-06-02

Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer

National Cancer Institute (NCI)

Phase 3 Completed
203 enrolled 22 charts
Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡